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Abstract: The guidelines for the use of androgen deprivation therapy (ADT) have changed 
significantly over the last 5 years. This paper reviews the current recommendations and documents 
the reasons for these changes, in a review of the world’s literature on ADT over the last 5 years. 
Special emphasis on randomized controlled trials and high-impact journals was included in the 
Medline search and review. One hundred articles on this topic written in the last 5 years were 
reviewed. Fifty-nine contained nonindustry-biased findings in major-impact journals and were 
available in English. The benefits of ADT are evident in several areas, including neoadjuvantly and 
adjuvantly in patients treated with external beam radiation therapy for intermediate- and high-risk 
disease; in patients who have undergone prostatectomy and who are found to have lymph node 
involvement on surgical resection; in high-risk patients after definitive therapy; and in patients 
who have developed symptomatic local progression or metastasis. This paper reviews the risks and 
benefits in each of these scenarios and the risks of androgen deprivation in general, and delineates the 
areas where ADT was previously recommended, but has been found to no longer be of benefit.
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Definition
Androgen deprivation is defined as a lowering of serum testosterone through the 
administration of an LHRH (leuteinizing hormone releasing hormone) agonist (unless 
otherwise specified) throughout this paper.
Introduction
The use of androgen deprivation therapy (ADT) for prostate cancer increased in the 
early part of the 21st century. In fact, its use increased so significantly, the payments for 
ADT constituted the second highest expense for Medicare part B expenditure in 2003.1 
The realization of this magnitude led to careful scrutiny of the risks and benefits of 
therapy as well as the restructuring of reimbursement for ADT by Medicare. This paper 
reviews the findings of investigations into the risks and benefits of ADT, delineates 
areas where its use has been deemed inappropriate/ineffective, and summarizes the 
current clinical situations where the use of ADT remains recommended.
The risks of ADT are becoming more fully elucidated. Multiple retrospective and 
prospective studies have been published recently, defining these risks. The administra-
tion of ADT can cost a patient physically, financially, and emotionally.
Adverse events associated with androgen deprivation
It is now well understood that the decreased lean body mass and increased body fat 
composition seen grossly with the administration of ADT2 is correlated with negative Cancer Management and Research 2009:1 100
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changes in the serum lipid profile, an increased risk of insulin 
resistance and an increased risk of coronary artery disease. 
This increase in cardiovascular disease correlates with an 
increase in myocardial infarction and even sudden cardiac 
death in some studies.3 This risk of the development of dia-
betes and coronary artery disease has been confirmed in other 
studies and appears to be even greater in men over 65 years 
of age.4 The description of this “metabolic syndrome” and the 
concern about its impact on survival on patients treated with 
ADT led to the reanalysis of the RTOG 92-02 trial. In this 
trial 1554 men with locally advanced prostate cancer were 
treated with neoadjuvant goserelin for 4 months prior to 
radiation therapy and either no additional therapy or for 
24 additional months. Although a striking increase in death 
from coronary artery disease was not seen in the men who 
underwent prolonged treatment with ADT, the authors did 
note that “although there was a significant advantage for all 
prostate cancer-specific end points [with prolonged therapy], 
the longer-term arm of ADT in RTOG 92-02 was associated 
with greater noncancer mortality than [the] short-term [arm].” 
They go on to state, “Compared to the general population, 
men with prostate cancer [are known to] have higher rates 
of non-cancer death and GnRH agonists may contribute to 
this through multiple mechanisms”.5 An interim analysis of 
a recent prospective randomized trial showed a reversal of 
the negative effects on low density lipoprotein (LDL), very 
low density lipoprotein (VLDL), and high density lipoprotein 
(HDL) with the administration of toremofine;6 a similar 
effect would likely be seen with 3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitors, or “statins.” A randomized 
prospective trial from Scandinavia showed that the use 
of estrogen, compared to ADT, decreased the risk of this 
“metabolic syndrome” as well as the risk osteoporosis but 
not surprisingly also increased the risk for thromboembolic 
event for a net negative improvement in adverse events with 
therapy.7 It is recommended at this time to screen carefully 
and treat all patients on ADT for hyperlipidemia, diabetes, 
and coronary artery disease.8
The risk of osteoporosis with ADT is real, appears early, 
and increases the risk of fracture.9 Unfortunately, hip fracture 
is a powerful independent predictor of early mortality.10 It is 
recommended that all men over 50, and particularly those 
treated with ADT be supplemented with 800 to 1000 IU of 
vitamin D, 1200 mg of calcium daily, frequent weight-bearing 
exercise, and be screened for osteoporosis regularly.11 Those at 
higher risk for fracture should be treated with bisphosphonates. 
A prospective randomized study of alendronate (70 mg weekly 
by mouth vs placebo) started at the initiation of ADT showed 
improvement of spine and hip densities and this finding 
was less significant if it was initiated after just one year of 
ADT.12 Quarterly or annual 4 mg zolendronic acid infusions 
for men with normal creatinine shows similar or even 
greater benefits, although the rare risk of osteonecrosis can 
be devastating.12–14 It is the official recommendation of the 
National Comprehensive Cancer Network that zoledronic acid 
be administered to men with bony progressive metastatic pros-
tate cancer on ADT to help prevent skeletal related events.
Although it would seem the financial costs of ADT are 
minimal, a recent study showed, if used for a significant 
amount of time, the cost of ADT would quickly be greater 
than that of radical prostatectomy or external beam therapy.15 
At a time when the cost to the government to cover medical 
costs for its citizens is rapidly approaching one half of the 
United States budget, this is not a trivial issue.
In addition to the adverse events seen with ADT on the 
cardiovascular, skeletal, and financial system, ADT may 
also have an effect on cognition and physical function. 
A retrospective trial showed that up to 27% of patients on 
ADT suffered a diagnosable psychiatric illness during their 
treatment, and that in patients on ADT tested over time, 
many lost cognition in one, if not two, measurable areas.16,17 
A recent prospective controlled study of men on androgen 
deprivation more than 6 months found a decline of lower body 
physical function with statistically slower walk and chair-rise 
times with treatment.18 A retrospective study from the Mayo 
Clinic in Scottsdale found that the average hemoglobin 
Table 1 Summary of androgen deprivation indications and recent changes
Less evidence for ADT in 2009 Still good uses for ADT in 2009
Localized dz – prior to prostatectomy21 Local/advanced dz – PSA  50, PSADT  12 mo29
Localized dz – prior to eBXRT, brachy tx24–27 Local/advanced dz – prior to eBXRT43–47
Localized dz – no primary treatment28 Local obstructive sx/metastatic disease52
Biochemical recurrence after tx, slow PSADT34 Biochem recurrence p tx, high-risk Cap death36–38
Lymph node involvement at prostatectomy49
Abbreviations: ADT, androgen deprivation therapy; EBXRT, external beam radiation; PSADT, prostate-specific antigen doubling time; dz, disease; tx, treatment; sx, symptoms; 
p, after; Cap, prostate cancer.Cancer Management and Research 2009:1 101
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drop on patients treated with LHRH antagonists is 1.6 g/dL 
which may contribute to the physical decline seen in these 
patients.19 As previous studies have found a profound and 
prolonged suppression of testosterone long after the cessation 
of LHRH analogues (53% of men remaining castrate up to 
2.5 years who had been on ADT for 4 or more years),20 there 
is concern that the adverse risks of coronary artery disease, 
diabetes, osteoporosis, cognitive/physical changes, and ane-
mia could persist beyond active therapy as well.
Although the risks of ADT are justified in some situations, 
the increased awareness of their magnitude, as well as data 
pointing to questionable efficacy have caused a shift in the 
recommendation to withdraw the recommend ADT in several 
clinical scenarios which will be reviewed below.
Androgen therapy 
not recommended
First, support for neoadjuvant androgen deprivation prior 
to or after prostatectomy has waned in men with localized 
disease. Although many studies have been done evaluating 
its efficacy and a possible decrease in positive surgical 
margins has been seen, no improvement in overall survival 
has been documented, making justification of the risks of 
ADT null.21 One of the largest prospective randomized 
prostate cancer trials, the Early Prostate Cancer (EPC) 
trial, evaluated 150 mg of bicaludamide daily in addition to 
standard therapy for men with low- and high-risk disease. 
Analysis of the overall trial did not show any advantage for 
its use in low-risk patients treated with surgery, radiation, 
or observation. Although in general antiandrogen mono-
therapy is thought to be inferior and less well tolerated that 
traditional androgen deprivation,22 the study did suggest 
some benefit in higher-risk patients with locally advanced 
or micro-metastatic disease in progression-free survival, but 
there was no benefit in overall survival.23
Similarly, although earlier studies might have suggested 
some benefit for neoadjuvant androgen deprivation prior 
to external beam radiation for low-risk patients, with 
higher dosing,24 conformal techniques that appear to make 
doses of 70 to 79 Gy possible with minimal toxicity,25 and 
the wider availability of brachytherapy, translate that, in 
general, neoadjuvant androgen deprivation is no longer 
recommended prior to radiation therapy for patients with 
low-risk prostate cancer.26,27
In fact, the results of a large retrospective trial recently 
published in JAMA evaluated 19,271 with localized prostate 
cancer. This study found that there was no increase in 10-year 
overall survival in men treated with androgen deprivation 
compared to conservative management, and indeed, there 
was a lower 10-year prostate-cancer specific survival in 
men treated with primary androgen deprivation.28 Similarly, 
when Dr Studer reported on the results of the EORTC trial 
where in 939 men with prostate cancer not suitable for local 
curative treatment were evaluated after their randomization 
to immediate vs deferred ADT, he concluded that “Patients 
with a baseline PSA  50 ng/mL and/or a PSADT 
[prostate-specific antigen doubling time] 12 months were 
at increased risk to die from prostate cancer and might have 
benefited from immediate ADT, whereas patients with a 
baseline PSA  50 ng/mL and a slow PSADT (12 months) 
were likely to die of cuases unrelated to prostate cancer, and 
thus could be spared the burden of immediate ADT”.29 The 
group of men with low risk tumors who do not get treated 
with ADT may benefit from active surveillance where similar 
rates of efficacy are achieved with decreased morbidity 
compared to definitive therapy or androgen deprivation.30,31 
With large trials suggesting little benefit seen in screening 
for prostate cancer (or at least a large number needed to 
treat to see benefit), particularly for men over 70, the cohort 
who may have previously been treated with ADT due to 
inability to tolerate definitive therapy may now be likely to 
avoid screening, diagnosis and overtreatment with androgen 
deprivation as well.32,33
Data following the natural course of men with recur-
rence after primary therapy show that very few die of their 
disease and that frequently competing causes of death and 
death from prostate cancer-specific death are equally likely 
upon recurrence of disease.34 A literature review published 
in JAMA concluded that “although patients with increasing 
prostate-specific antigen levels after local treatment without 
metastatic disease frequently undergo ADT, the benefits of 
this strategy are not clear… and need to be weighed carefully 
against substantial risks and adverse effects on quality of 
life”.35 This observation has led to the recommendation 
of a risk-stratified approach. This approach includes the 
incorporation of known risk factors for recurrent aggressive 
disease to define which patients need more aggressive, early 
therapy and which patients may be able to be spared the 
adverse events of androgen deprivation at the detection of 
biochemical recurrence. The elements of risk-stratification 
may include pretreatment PSA, PSA velocity, Gleason 
score, volume of tumor or stage,36–38 PSA velocity or total 
value,29,39 PSA nadir and time to recurrence after therapy40,41 
and possibly the presence of circulating tumor cells,42 as all 
of these have been shown to be associated with increased 
risk of progression or death from prostate cancer.Cancer Management and Research 2009:1 102
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Androgen therapy recommended
Clearly the risk of ADT is worth the possible benefit in men 
with high stage, high grade tumors, with rapid recurrence 
after therapy, doubling times under 12 months and/or total 
PSA values greater than 50 ng/mL. These men should also 
have consultation with medical oncology early and should 
be considered strongly for clinical trials.
Additional scenarios where ADT should be strongly 
considered and has been proven to provide benefit include: 
neoadjuvantly/adjuvantly ADT in patients with intermediate/
high-risk prostate cancer treated with external beam radiation 
therapy; adjuvantly after prostatectomy in patients found to 
have lymph node involvement on surgical resection; and in 
patients who have developed (symptomatic) bony metastasis 
or locally obstructive symptoms. Support for ADT in these 
situations will be described below.
The administration of neoadjuvant ADT remains an 
independent predictor of long-term control in patients 
with intermediate and high risk cancer treated with 
external beam radiation (EBXRT) and should be given 
prior to therapy.43,44 A randomized trial of 802 Australian 
men found that 3 months of neo-adjuvant ADT showed an 
inferior prostate cancer-specific mortality to men treated 
with 6 months in men with locally advanced prostate 
cancer, so a treatment with 4 to 6 months of neoadjuvant 
ADT is recommended prior to external beam radiation.45 
The initial finding in the randomized controlled RTOG/
EORTC trials showing that an additional 24 to 36 
months of ADT after EBXRT improves survival in men 
with high risk disease and is recommended as well.46,47 
In these trials androgen deprivation has been achieved 
using an LHRH agonist as well as an antiandrogen. 
Similar efficacy may be able to be achieved with LHRH 
monotherapy, but formal comparative studies have not 
been performed. Interestingly, when a group in Spain 
looked at predictors for hematuria in patients who had 
undergone conformal prostate radiation for cancer, 
the administration of adjuvant androgen deprivation 
was protective (a factor of 5) for the development of 
hematuria (whereas transurethral resection [TURP] 
increased the risk three times).48
There is support for immediate ADT in men found to 
have lymph node involvement at prostatectomy. Only one 
randomized, controlled has been performed to investigate this 
situation to date. Although this trial is small and may have 
exaggerated survival advantages by delaying the initiation 
of ADT in the initially nontreated group, the study showed 
a significant improvement in overall, disease-specific, and 
progression-free survival advantage for patients who undergo 
early ADT in this setting.49
In men wishing to undergo brachytherapy, but who have 
a prostate too large to be treated effectively, ADT can be 
considered. Similar results may be achieved with 5-alpha 
reductase inhibitors or even antiandrogens alone as well 
(with appropriate prevention of gynecomastia), and may be 
preferred.50
In men wishing to undergo salvage or primary cryotherapy 
for prostate cancer, the largest series in the literature reports 
success when ADT is used adjuvantly. This strategy may be 
beneficial with this treatment modality.51 Meaningful studies 
comparing ADT with cryotherapy to cryotherapy alone have 
not been performed to my knowledge.
Finally, data from the MRC trial published in 1997 
showing that ADT helps decrease symptoms from patients 
with advanced disease is still to be considered today. This 
prospective randomized trial of 938 men with locally 
advanced or asymptomatic metastatic prostate cancer showed 
that rates of pathological fracture, spinal cord compression, 
urteric obstruction, the development of extra-skeletal 
metastases (and pain from these metastases) as well as death 
from prostate cancer are statistically more common in men 
who were not treated with early androgen deprivation.52 
It is important to note that since the introduction of PSA 
screening there has been a significant stage migration down-
ward, so patients with this level of disease burden may be 
less common.
Future research
Additional investigation to the risk and benefit of the 
primary use or adjuvant use of other agents in this area 
such as somatostatin or NF-kB ligand (RANKL) receptor 
antagonists, RNF6-ubiquitiniation inhibitors, aromatase 
inhibitors, or long-term antiandrogen monotherapy23,53–55 is 
being performed. The use of agents to reduce production 
of dihydrotestosterone in the prevention of prostate cancer 
is interesting, but so far does not appear to improve the 
efficacy of complete androgen blockade in men with 
castration recurrent prostate cancer.56 The use of 1alpha, 
25-dihydroxy vitamin D3 downregulates the expression 
of prostate specific membrane antigen in prostate cancer 
cells.57 There is a possibility that these agents may improve 
the efficacy profile of ADT and/or decrease its side effect 
profile. LHRH antagonists have not been fully studied in 
all of the scenarios mentioned above but are predicted 
to have a similar effect to LHRH agonists given with an 
antiandrogen for the first seven days as their suppression of Cancer Management and Research 2009:1 103
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testosterone is similar.58,59 Additionally, it will be exciting 
to see if new pharmaceutical agents such as abiraterone and 
MDV 3100, which inhibit testosterone in different ways, 
have as much promise as is anticipated with additional 
study.
Summary
In summary, the risks of ADT have been more elaborated 
over the last 5 years and are significant. Patients should 
be appraised of these risks and should undergo monitoring 
for hyperlipidemia, coronary artery disease, osteoporosis, 
and diabetes while castrate. The initiation of calcium and 
vitamin D therapy are recommended with the initiation 
of ADT (for men who are not already on it), with the 
consideration of oral of intravenous bisphosphonates 
for those with metastatic disease or osteoporosis. ADT 
is discouraged in conjunction with prostatectomy unless 
local lymph nodes are found to be involved. ADT is 
generally not recommended with adequate (70 to 79 Gy) 
conformal (145 Gy), or brachytherapy radiation in patients 
with low-risk disease. And ADT should not be considered 
primary therapy for men with low-risk prostate cancer. 
In men with a biochemical (PSA-only) recurrence after 
primary therapy, the timing of the initiation of ADT should 
be considered carefully. Those patients with high stage 
(2b), high grade tumors 7, with rapid PSA velocities 
before and/or after treatment (total PSA  10 ng/mL 
before treatment, doubling time 12 months or absolute 
increase of 2 ng/mL/year before or after treatment), PSA 
nadir 0.2 ng/mL, or overall high total PSA (50 ng/mL) 
likely benefit from early intervention and possibly from 
involvement in a clinical trial. Additional situations where 
ADT is strongly recommended are: in a neoadjuvant and 
setting for 4 to 6 months in men with intermediate risk 
cancer undergoing radiation therapy or for men with large 
prostates and low-risk cancer anticipating brachytherapy; 
in an adjuvant setting for 2 to 3 years in men with 
high-risk prostate cancer undergoing radiation therapy; 
in men found to have positive nodes at prostatectomy; 
and in men with symptomatic (obstructing or painful) 
locally advanced or metastatic disease. ADT may be 
considered adjuvantly or neoadjuvantly in patients being 
treated with cryotherapy. Studies to identify agents that 
are equally effective but that have fewer adverse effects 
are ongoing.
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